These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39218851)

  • 1. Multi-omics and clustering analyses reveal the mechanisms underlying unmet needs for patients with lung adenocarcinoma and identify potential therapeutic targets.
    Asada K; Kaneko S; Takasawa K; Shiraishi K; Shinkai N; Shimada Y; Takahashi S; Machino H; Kobayashi K; Bolatkan A; Komatsu M; Yamada M; Miyake M; Watanabe H; Tateishi A; Mizuno T; Okubo Y; Mukai M; Yoshida T; Yoshida Y; Horinouchi H; Watanabe SI; Ohe Y; Yatabe Y; Kohno T; Hamamoto R
    Mol Cancer; 2024 Sep; 23(1):182. PubMed ID: 39218851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations.
    Kaneko S; Takasawa K; Asada K; Shiraishi K; Ikawa N; Machino H; Shinkai N; Matsuda M; Masuda M; Adachi S; Takahashi S; Kobayashi K; Kouno N; Bolatkan A; Komatsu M; Yamada M; Miyake M; Watanabe H; Tateishi A; Mizuno T; Okubo Y; Mukai M; Yoshida T; Yoshida Y; Horinouchi H; Watanabe SI; Ohe Y; Yatabe Y; Saloura V; Kohno T; Hamamoto R
    Mol Cancer; 2024 Jun; 23(1):126. PubMed ID: 38862995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals immune suppression subtypes and establishes a novel signature for determining the prognosis in lung adenocarcinoma.
    Mao S; Wang Y; Chao N; Zeng L; Zhang L
    Cell Oncol (Dordr); 2024 Oct; 47(5):1697-1713. PubMed ID: 38616208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive characterization of functional eRNAs in lung adenocarcinoma reveals novel regulators and a prognosis-related molecular subtype.
    Qin N; Ma Z; Wang C; Zhang E; Li Y; Huang M; Chen C; Zhang C; Fan J; Gu Y; Xu X; Yang L; Wei X; Yin R; Jiang Y; Dai J; Jin G; Xu L; Hu Z; Shen H; Ma H
    Theranostics; 2020; 10(24):11264-11277. PubMed ID: 33042282
    [No Abstract]   [Full Text] [Related]  

  • 5. Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma.
    Zhao Y; Gao Y; Xu X; Zhou J; Wang H
    BMC Cancer; 2021 Mar; 21(1):257. PubMed ID: 33750346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of GCLC in prognosis and immunity of lung adenocarcinoma and multi-omics regulation mechanisms.
    Huang Z; Liang F; Wu J; Huang Z; Li Y; Huang X; Liu Z
    BMC Pulm Med; 2024 May; 24(1):239. PubMed ID: 38750474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic Effects of Different Levels of Genomic Data for the Staging of Lung Adenocarcinoma: An Illustrative Study.
    Li Y; Mansmann U; Du S; Hornung R
    Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated multi-omics analysis and machine learning to refine molecular subtypes, prognosis, and immunotherapy in lung adenocarcinoma.
    Han T; Bai Y; Liu Y; Dong Y; Liang C; Gao L; Zhou J; Guo J; Wu J; Hu D
    Funct Integr Genomics; 2024 Jun; 24(4):118. PubMed ID: 38935217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancing lung adenocarcinoma prognosis and immunotherapy prediction with a multi-omics consensus machine learning approach.
    Lin H; Zhang X; Feng Y; Gong Z; Li J; Wang W; Fan J
    J Cell Mol Med; 2024 Jul; 28(13):e18520. PubMed ID: 38958523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating multi-omics and machine learning survival frameworks to build a prognostic model based on immune function and cell death patterns in a lung adenocarcinoma cohort.
    Xie Y; Chen H; Tian M; Wang Z; Wang L; Zhang J; Wang X; Lian C
    Front Immunol; 2024; 15():1460547. PubMed ID: 39346927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel genome-wide DNA methylation profiling reveals distinct epigenetic landscape, prognostic model and cellular composition of early-stage lung adenocarcinoma.
    Gan J; Huang M; Wang W; Fu G; Hu M; Zhong H; Ye X; Cao Q
    J Transl Med; 2024 May; 22(1):428. PubMed ID: 38711158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-omics analysis reveals epigenetically regulated processes and patient classification in lung adenocarcinoma.
    Brativnyk A; Ankill J; Helland Å; Fleischer T
    Int J Cancer; 2024 Jul; 155(2):282-297. PubMed ID: 38489486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi‑omics identification of a signature based on malignant cell-associated ligand-receptor genes for lung adenocarcinoma.
    Xu S; Chen X; Ying H; Chen J; Ye M; Lin Z; Zhang X; Shen T; Li Z; Zheng Y; Zhang D; Ke Y; Chen Z; Lu Z
    BMC Cancer; 2024 Sep; 24(1):1138. PubMed ID: 39267056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
    Zengin T; Önal-Süzek T
    BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival.
    Li T; Liu J; Zhou Y; Huang S; Wang D; Chen J; Fu Y; He P
    Cancer Med; 2024 May; 13(10):e7227. PubMed ID: 38770632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A methylation-related lncRNA-based prediction model in lung adenocarcinomas.
    Yang K; Liu H; Li JH
    Clin Respir J; 2024 Aug; 18(8):e13753. PubMed ID: 39187946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling.
    El Zarif T; Meador CB; Qiu X; Seo JH; Davidsohn MP; Savignano H; Lakshminarayanan G; McClure HM; Canniff J; Fortunato B; Li R; Banwait MK; Semaan K; Eid M; Long H; Hung YP; Mahadevan NR; Barbie DA; Oser MG; Piotrowska Z; Choueiri TK; Baca SC; Hata AN; Freedman ML; Berchuck JE
    Clin Cancer Res; 2024 Sep; 30(17):3798-3811. PubMed ID: 38912901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of TPX2-related ceRNA network as prognostic biomarkers in lung adenocarcinoma.
    Huo C; Zhang MY; Li R; Zhou XJ; Liu TT; Li JP; Liu X; Qu YQ
    Int J Med Sci; 2020; 17(16):2427-2439. PubMed ID: 33029085
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.